Trial · NCT05656027

Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

NCT05656027, Phase 3, Completed, LENZ Therapeutics, Inc; results first posted 2026-02-25

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia. Trials, record NCT05656027. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05656027

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia
NCT number: NCT05656027
Status: Completed
Phases: Phase 3
Enrollment: 469 participants, actual
Lead sponsor: LENZ Therapeutics, Inc
Conditions: Presbyopia, Refractive Error, Eye Diseases, Near Vision
Interventions: Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Brimonidine
First posted: 2022-12-19
Last updated: 2026-05-13
Results first posted: 2026-02-25

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision	3 hours post-treatment in the study eye on Day 1	Percentage of participants with at least a 3-line improvement in near vision and no loss ≥ 5 letters distance vision on Day 1

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision	3 hours post-treatment in the study eye on Day 1		percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision	Aceclidine + Brimonidine (LNZ101)	48.68	95% Confidence Interval 40.823 to 56.547	percentage of participants
Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision	Aceclidine Ophthalmic Solution (LNZ100)	64.5	95% Confidence Interval 57.076 to 71.920	percentage of participants
Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision	Brimonidine Ophthalmic Solution	11.49	95% Confidence Interval 6.515 to 16.464	percentage of participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Aceclidine + Brimonidine (LNZ101)	156
Overall Study	STARTED	Aceclidine Ophthalmic Solution (LNZ100)	157
Overall Study	STARTED	Brimonidine Ophthalmic Solution	156
Overall Study	COMPLETED	Aceclidine + Brimonidine (LNZ101)	144
Overall Study	COMPLETED	Aceclidine Ophthalmic Solution (LNZ100)	150
Overall Study	COMPLETED	Brimonidine Ophthalmic Solution	148
Overall Study	NOT COMPLETED	Aceclidine + Brimonidine (LNZ101)	12
Overall Study	NOT COMPLETED	Aceclidine Ophthalmic Solution (LNZ100)	7
Overall Study	NOT COMPLETED	Brimonidine Ophthalmic Solution	8

Source ClinicalTrials.gov

Adverse events21

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Visual Impairment	Eye disorders	Aceclidine + Brimonidine (LNZ101)	28	156
other	Visual Impairment	Eye disorders	Aceclidine Ophthalmic Solution (LNZ100)	16	157
other	Visual Impairment	Eye disorders	Brimonidine Ophthalmic Solution	0	156
other	Vision blurred	Eye disorders	Aceclidine + Brimonidine (LNZ101)	6	156
other	Vision blurred	Eye disorders	Aceclidine Ophthalmic Solution (LNZ100)	5	157
other	Vision blurred	Eye disorders	Brimonidine Ophthalmic Solution	15	156
other	Ocular Hyperaemia	Eye disorders	Aceclidine + Brimonidine (LNZ101)	8	156
other	Ocular Hyperaemia	Eye disorders	Aceclidine Ophthalmic Solution (LNZ100)	7	157
other	Ocular Hyperaemia	Eye disorders	Brimonidine Ophthalmic Solution	0	156
other	Instillation Site Irritation	General disorders	Aceclidine + Brimonidine (LNZ101)	31	156

1 to 10 of 21Source ClinicalTrials.gov

See all 21 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Aceclidine + Brimonidine (LNZ101)	0	156
Total, all-cause mortality	Aceclidine Ophthalmic Solution (LNZ100)	0	157
Total, all-cause mortality	Brimonidine Ophthalmic Solution	0	156
Total, other adverse events	Aceclidine + Brimonidine (LNZ101)	73	156
Total, other adverse events	Aceclidine Ophthalmic Solution (LNZ100)	53	157
Total, other adverse events	Brimonidine Ophthalmic Solution	25	156
Total, serious adverse events	Aceclidine + Brimonidine (LNZ101)	3	156
Total, serious adverse events	Aceclidine Ophthalmic Solution (LNZ100)	0	157
Total, serious adverse events	Brimonidine Ophthalmic Solution	0	156

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05656027

GET https://conductscience.org/api/trials/v1/NCT05656027/events?page=2

API reference For AI assistants